Delivery Order HHSN272201600004I-HHSN27200002
- This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract, valued at $1,826,332.06, is for the provision of preclinical development support services related to the NIAID's infectious disease research and product development...
- This is a $3,500 firm-fixed-price delivery order awarded to Advanced Bioscience Laboratories, Inc. (ABL) by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health. The order is under the NIAID's Diagnostics Pre-Clinical Services Program Indefinite Delivery Vehicle (IDV), which has a total ceiling value of $24 million. ABL, a foreign-owned, for-profit manufacturer, is providing a range of preclinical development services to support...
- This is a $2,696,523.00 delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer, for NIAID's Preclinical Development Support program. The contract has a period of performance through December 31, 2026 and is a cost-plus-fixed-fee type. ABL, a leading contract research and manufacturing organization, provides a range of preclinical and clinical development services to support...
- This is a new task order award under contract #HHSN272201800009I to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of biologics. The $531,739.51 cost-plus-fixed-fee contract is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and is focused on the development of mucosal vaccine technologies. ABL is a leading contract research organization with extensive experience supporting the preclinical...
- This is a prime contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL) on September 20, 2017. The contract has a potential value of $2,044,103.00 and is a Delivery Order for NIAID Preclinical Development Support services. The contract has a completion date of December 31, 2022 and is not set-aside. ABL is a contract research and...
- This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL). The $13,047,649.73 contract is for "ESSENTIAL CORE ACTIVITIES, NIAID PRECLIN DEVELOPMENT SUPPORT" and does not have a set-aside designation. ABL is a foreign-owned, for-profit manufacturing company that specializes in the development of gene...
- This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The contract, with a ceiling value of $186,316.03, is for the manufacture and characterization of vaccines and other biologics. ABL, a foreign-owned, for-profit organization that specializes in biopharmaceutical research and development, is a leading contract research and manufacturing...
- This is a delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL). The contract is for $1,812,395.46 and provides for the manufacture and characterization of vaccines and other biologics. The contract does not have a set-aside designation. ABL is a foreign-owned, for-profit organization that specializes in the development of gene...
- This is a definitive, cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods. The contract, valued at $213,045,738.00, is for preclinical development services to support infectious disease research and product development initiatives. The contract does not have a set-aside designation. ABL has been awarded numerous federal contracts and grants,...
- Advanced Bioscience Laboratories, Inc. (ABL) was awarded a delivery order contract valued at $2.1M by the National Institute of Allergy and Infectious Diseases (NIAID) on June 10, 2017, under the Essential Core Activities III program for Preclinical Development Support. The contract, which operates on a cost-plus-fixed-fee basis with no set-aside designation, is scheduled for completion by June 8, 2029, and will be performed in Potomac, Maryland. As a leading contract research and...
- HHSN272201600004IIndefinite Delivery Contract
- HHSN272201600004I-HHSN27200002Delivery Order
This is a task order awarded under the Preclinical Services for Biopharmaceutical Product Development indefinite-delivery/indefinite-quantity (IDIQ) contract by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases. The $110,115.92 task order was awarded to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit organization that specializes in manufacturing and testing biologics such as gene therapies, vaccines, and immunotherapies. ABL has been awarded over $35 million in federal contracts to support preclinical and clinical product development for agencies including the NIH and Department of Health and Human Services. This task order does not have a set-aside designation and was awarded on September 6, 2017, with a completion date of April 13, 2018.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Funding Only Action | $8.5k | 8/7/23 | |
| 1 | Other Administrative Action | $0 | 1/19/18 | |
| Not listed | Not listed | $101.6k | 9/6/17 |